Komori
Rohto Pharmaceutical (4527) · FactRestated

Change of Audit Firm

First written in FY2020-Q1. 12 of 13 entries say "Restated". Latest entry: FY2024-Q3.

13entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2020-Q1 – FY2024-Q32019: 220192020: 320202021: 320212022: 220222023: 220232024: 1
Same theme, other companies
Change in Audit Firm and Quarterly Review FrameworkA theme 125 companies write about · 1 as a headwind · 1 as a tailwind

88 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 125 companies compared. The sentences above are computed from all 125.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3RestatedAnnual report

    「Pursuant to Article 193-2, paragraph 1 of the Financial Instruments and Exchange Act, we have received a quarterly review by EY ShinNihon LLC of the quarterly consolidated financial statements for the third-quarter consolidated accounting period (1 October 2023 to 31 December 2023) and the third-quarter consolidated cumulative period (1 April 2023 to 31 December 2023).」

    The third-quarter review by Ernst & Young ShinNihon LLC after the audit firm changed has been reconfirmed.
  2. FY2024-Q2RestatedAnnual report

    「Pursuant to Article 193-2, paragraph 1 of the Financial Instruments and Exchange Act, we have received a quarterly review by EY ShinNihon LLC of the quarterly consolidated financial statements for the second-quarter consolidated accounting period (1 July 2023 to 30 September 2023) and the second-quarter consolidated cumulative period (1 April 2023 to 30 September 2023).」

    The second-quarter review by Ernst & Young ShinNihon LLC has been reconfirmed.
  3. FY2024-Q1RestatedAnnual report

    「Pursuant to Article 193-2, paragraph 1 of the Financial Instruments and Exchange Act, we have received a quarterly review by EY ShinNihon LLC of the quarterly consolidated financial statements for the first-quarter consolidated accounting period (1 April 2023 to 30 June 2023) and the first-quarter consolidated cumulative period (1 April 2023 to 30 June 2023).」

    The first-quarter review by Ernst & Young ShinNihon LLC after the audit firm changed has been reconfirmed.
  4. FY2023-Q2RestatedAnnual report

    「Pursuant to Article 193-2, paragraph 1 of the Financial Instruments and Exchange Act, we have received a quarterly review by EY ShinNihon LLC of the quarterly consolidated financial statements for the second-quarter consolidated accounting period (1 July 2022 to 30 September 2022) and the second-quarter consolidated cumulative period (1 April 2022 to 30 September 2022).」

    The second-quarter review by Ernst & Young ShinNihon LLC after the audit firm changed has been reconfirmed.
  5. FY2023-Q1RestatedAnnual report

    「Pursuant to Article 193-2, paragraph 1 of the Financial Instruments and Exchange Act, the company has undergone a quarterly review by EY ShinNihon LLC of its quarterly consolidated financial statements for the first quarter consolidated accounting period (1 April 2022 to 30 June 2022) and the first quarter consolidated cumulative period (1 April 2022 to 30 June 2022).」

    The first-quarter review by Ernst & Young ShinNihon LLC has been reconfirmed.
  6. FY2022-Q2RestatedAnnual report

    「Pursuant to Article 193-2, paragraph 1 of the Financial Instruments and Exchange Act, we have received a quarterly review by EY ShinNihon LLC of the quarterly consolidated financial statements for the second-quarter consolidated accounting period (1 July 2021 to 30 September 2021) and the second-quarter consolidated cumulative period (1 April 2021 to 30 September 2021).」

    The second-quarter review by Ernst & Young ShinNihon LLC after the audit firm changed has been reconfirmed.
  7. FY2022-Q1RestatedAnnual report

    「Pursuant to Article 193-2, paragraph 1 of the Financial Instruments and Exchange Act, we have received a quarterly review by EY ShinNihon LLC of the quarterly consolidated financial statements for the first-quarter consolidated accounting period (1 April 2021 to 30 June 2021) and the first-quarter consolidated cumulative period (1 April 2021 to 30 June 2021).」

    The first-quarter review by Ernst & Young ShinNihon LLC after the audit firm changed has been reconfirmed.
  8. FY2021-Q3RestatedAnnual report

    「The quarterly consolidated financial statements for the third quarter of the consolidated fiscal period (1 October 2020 to 31 December 2020) and the cumulative third quarter (1 April 2020 to 31 December 2020) have been reviewed by Ernst & Young ShinNihon LLC.」

    The third-quarter review by Ernst & Young ShinNihon LLC after the audit firm changed has been reconfirmed.
  9. FY2021-Q2RestatedAnnual report

    「The quarterly consolidated financial statements for the second quarter of the current consolidated fiscal period (1 July 2020 to 30 September 2020) and the cumulative second quarter (1 April 2020 to 30 September 2020) have been reviewed by Ernst & Young ShinNihon LLC.」

    The second-quarter review by Ernst & Young ShinNihon LLC after the audit firm changed has been reconfirmed.
  10. FY2021-Q1RestatedAnnual report

    「The quarterly consolidated financial statements for the first quarter of the current consolidated fiscal period (1 April 2020 to 30 June 2020) and the cumulative first quarter (1 April 2020 to 30 June 2020) have been reviewed by Ernst & Young ShinNihon LLC.」

    The quarterly review by Ernst & Young ShinNihon LLC after the audit firm changed has been reconfirmed.
  11. FY2020-Q3RestatedAnnual report

    「The quarterly consolidated financial statements for the third quarter of the current consolidated fiscal period (1 October 2019 to 31 December 2019) and the cumulative third quarter (1 April 2019 to 31 December 2019) have been reviewed by Ernst & Young ShinNihon LLC.」

    It has been reconfirmed that the third-quarter consolidated financial statements were subject to a quarterly review by Ernst & Young ShinNihon LLC.
  12. FY2020-Q2RestatedAnnual report

    「The quarterly consolidated financial statements for the second quarter of the current consolidated fiscal period (1 July 2019 to 30 September 2019) and the cumulative second quarter (1 April 2019 to 30 September 2019) have been reviewed by Ernst & Young ShinNihon LLC.」

    It has been reconfirmed that the second-quarter consolidated financial statements were subject to a quarterly review by Ernst & Young ShinNihon LLC.
  13. FY2020-Q1First statedAnnual report

    「The Company's audit firm has changed as follows. Consolidated fiscal year 83: KPMG AZSA LLC. First quarter of consolidated fiscal year 84 and cumulative first quarter: Ernst & Young ShinNihon LLC.」

    The fact that the audit firm changed from KPMG AZSA LLC to Ernst & Young ShinNihon LLC from the first quarter of fiscal year 84 has been disclosed.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Rohto Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.